Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opdivo
Biotech
ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial
IO Biotech's cancer vaccine, in combination with Keytruda, delivered an objective response rate of 44.4%, hitting the study's primary endpoint.
Darren Incorvaia
Sep 14, 2024 2:30am
ASCO: Early Purple Biotech data shows gains in pancreatic cancer
Jun 1, 2024 8:00am
BMS plans $1.5B in cuts through '25, with 2,000-plus layoffs
Apr 25, 2024 8:40am
Ono taps Shattuck for $227M bifunctional fusion protein deal
Feb 13, 2024 8:29am
Ultimovacs links BMS-cancer vaccine combo to improved survival
Oct 18, 2023 8:40am
Long survival spurs Ultimovacs to mull ways to end cancer trial
Aug 22, 2023 10:00am
